- Signaling Pathways
- Cytoskeleton
- Cdc42-binding kinase
Cdc42-binding kinase
Cdc42-binding kinase; myotonic dystrophy kinase-related Cdc42-binding kinases; MRCK
There are three subtypes of MRCK in humans: α, β, and γ. α and β are widely expressed, and γ is mainly expressed in muscle tissue. All three contain CRIB motifs and can bind to Cdc42/Rac1. The γ subunit has a preference for TC10[1][2].
Cdc42-binding kinase promotes actomyosin contraction by phosphorylating myosin regulatory light chain (MLC2) Ser19 and inhibiting myosin phosphatase (MLCP) subunit MYPT1, and participates in the establishment of cell polarity, directional migration, neurite growth, epithelial cell apical contraction, and cancer cell invasion. It can also phosphorylate LIMK1 to stabilize actin fibers.
Mechanistically, Cdc42-binding kinase binds to activated Cdc42-GTP through the CRIB motif, binds to membrane lipids such as phosphatidylserine (PS) with the help of C1 and PH domains, and localizes to the cell membrane; the coiled-coil domain mediates dimerization and maintains the active conformation of the kinase, binds to the actomyosin complex through the adaptor protein LRAP25/35a, such as LRAP35a mediating the binding of MRCK to MYO18A, and regulating the dynamics of lamellipodia actin fibers. At the same time, Cdc42-binding kinase participates in the Cdc42 and Rac1 signaling pathways, and is recruited to specific membrane regions by binding to GTP-formed Cdc42/Rac1, synergistically regulating the reorganization of the actin skeleton[1][2].
Interacting proteins of Cdc42-binding kinase include small GTPases CDC42 and Rac1, membrane lipids such as PS, inositol bisphosphates (PIPs), adaptor proteins LRAP25/35a, Shroom (ROCK-like adaptor protein), and actin-related proteins MYO18A and LIMK1[1][2].
Among the inhibitors of Cdc42-binding kinase, BDP5290 (HY-12437) is a selective inhibitor of MRCK, which is more than 50 times more selective for MRCKβ than ROCK and can block cancer cell invasion; Chelerythrine (HY-N2359) inhibits the activity of MRCK by binding to its C1 domain, affecting the formation of sheet-like actin fibers, with an IC50 of 1.8 μM, but there is a non-target effect[1][2].
In summary, MRCK abnormalities may be closely related to cancer cell migration and invasion, and its inhibitors are potential anticancer drugs. In developmental biology, MRCK is involved in embryonic gastrulation and the establishment of epithelial cell polarity, and its abnormal function may lead to developmental defects; in addition, the specific expression of MRCKγ in muscle tissue suggests that it may be associated with the pathological mechanism of muscle-related diseases such as myotonic dystrophy, but its specific role still needs further study[1][2].
- [1]. Zhao Z, et al. Myotonic dystrophy kinase-related Cdc42-binding kinases (MRCK), the ROCK-like effectors of Cdc42 and Rac1. Small GTPases. 2015;6(2):81-8. [Content Brief]
- [2]. Truebestein L, et al. Structure and regulation of the myotonic dystrophy kinase-related Cdc42-binding kinase. Structure. 2023 Apr 6;31(4):435-446.e4. [Content Brief]
Cdc42-binding kinase Isoform Specific Products
All Product Categories
-
Cdc42-binding kinase Related Products (6)
Related Products (6)
-
Cdc42-binding kinase Isoform Comparison
-
BDP9066
0 ImagesBDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
(R)-BDP9066
0 ImagesCat. No.: HY-111424ACAS No.: 2284549-25-1(R)-BDP9066 is an isomer of BDP9066 and has lower activity compared to BDP9066. BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 is derived from patent WO2019034890A1 (E118). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- DJ4
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Rac/Cdc42-IN-1
0 ImagesCat. No.: HY-183246CAS No.: 2143950-05-2Rac/Cdc42-IN-1, the major phase I metabolite of the oral Rac/Cdc42 inhibitor MBQ-167 (HY-112842) in vivo, is a selective Rac inhibitor. Rac/Cdc42-IN-1 functions by blocking the GTP-binding activation of Rac1, targeting the autophosphorylation of Thr423/Thr402/Thr436 and Ser141/Ser144/Ser154 in downstream PAK1/2/3, with an inhibitory effect superior to that of MBQ-167. Rac/Cdc42-IN-1 significantly inhibits cell migration, and suppresses tumor growth and distant metastasis to the lung, liver and kidney in HER2+ breast cancer mouse models. Rac/Cdc42-IN-1 can be used for targeted research on metastatic breast cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
BDP8900
0 ImagesCat. No.: HY-111423CAS No.: 2226507-05-5BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ). BDP8900 reduces substrate phosphorylation, leading to morphological changes, motility inhibition and invasiveness of cancer cells. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
4A-MPLA ammonium
0 ImagesCat. No.: HY-N16021CAS No.: 2260669-09-64A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.